1332498-38-0

Basic information

• Product Name: 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-1-isopropylpiperidine
• Synonyms: 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-1-isopropylpiperidine
• CAS NO: 1332498-38-0
• Molecular Weight: 371.48
• Mol File: 1332498-38-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-1-isopropylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-1-isopropylpiperidine(1332498-38-0)
• EPA Substance Registry System: 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-1-isopropylpiperidine(1332498-38-0)

Safety Data

• Hazardous Substances Data: 1332498-38-0(Hazardous Substances Data)

Upstream product

• 1332498-35-7 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 713147-49-0 4-(N-hydroxycarbamimidoylmethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 30461-77-9 methyl 3,4-dimethoxycinnamate 
• 41979-39-9 4-piperidone hydrochloride 
• 256411-39-9 tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate 
• 197569-11-2 4-(cyanomethylidene)piperidine-1-carboxylic acid tert-butyl ester 
• 1332498-36-8 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-piperidine 
• 75-26-3 isopropyl bromide 
• 120-14-9 3,4-dimethoxy-benzaldehyde 

Downstream Products

• 1332498-39-1 4-{2-[3-(1-isopropyl-piperidin-4-ylmethyl)-[1,2,4]oxadiazol-5-yl]-vinyl}-benzene-1,2-diol 

Relevant articles and documents

OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE

The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.